Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 16/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15793536 | 0.90 | HTT (0.55) | ELANETDP1HTTL3MBTL1CYP2C9 | |
| SCHEMBL15793304 | 0.90 | HTT (0.55) | ELANETDP1HTTL3MBTL1CYP2C9 | |
| SCHEMBL14760482 | 0.88 | ELANE (0.70) | ELANETDP1HTTL3MBTL1CYP2C9 | |
| SCHEMBL2678551 | 0.88 | ELANE (0.70) | ELANETDP1HTTL3MBTL1CYP2C9 | |
| SCHEMBL2679242 | 0.83 | ELANE (0.71) | ELANECYP2C9 | |
| SCHEMBL2678247 | 0.80 | ELANE (0.84) | ELANECYP2C9 | |
| SCHEMBL21266875 | 0.79 | ELANE (0.83) | ELANECYP2C9 | |
| SCHEMBL8344863 | 0.79 | ELANE (0.83) | ELANECYP2C9 | |
| SCHEMBL14760555 | 0.79 | ELANE (0.83) | ELANECYP2C9 | |
| SCHEMBL17311447 | 0.79 | TDP1 (0.54) | ELANETDP1HTTL3MBTL1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154980-B1 | TETRAHYDROTRIAZOLOPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES | CHIESI FARM SPA (IT) | 2021-08-04 | — | — | EP | disclosed |
| EP-3154980-B1 | TETRAHYDROTRIAZOLOPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES | CHIESI FARM SPA (IT) | 2021-08-04 | — | — | EP | disclosed |
| US-9487528-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-11-08 | — | — | US | disclosed |
| US-9487528-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-11-08 | — | — | US | disclosed |
| US-9487528-B2 | Compounds | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-11-08 | — | — | US | disclosed |
| WO-2015189362-A1 | TETRAHYDROTRIAZOLOPYRIMIDINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-17 | — | — | WO | disclosed |
| US-20150353561-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-10 | — | — | US | disclosed |
| US-20150353561-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-10 | — | — | US | disclosed |
| US-20150353561-A1 | NOVEL COMPOUNDS | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353561-A1 | NOVEL COMPOUNDS | SERPINB1, ELANE, MPO | ELANE 2/4885TDP1 1812/4885HTT 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.